Get the Stockscreener App
137.39
0.68%
-1.05
Glaukos Corporation stock is traded at $137.39, with a volume of 159.60K.
It is down -0.68% in the last 24 hours and up +3.10% over the past month.
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
See More
Previous Close:
$138.44
Open:
$139
24h Volume:
159.60K
Relative Volume:
0.32
Market Cap:
$7.66B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-51.07
EPS:
-2.69
Net Cash Flow:
$-81.27M
1W Performance:
-3.87%
1M Performance:
+3.10%
6M Performance:
+25.24%
1Y Performance:
+114.64%
1-Day Range:
$136.86
$139.80
1-Week Range:
$136.86
$145.84
52-Week Range:
$59.22
$145.84
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| GKOS | 137.42 | 7.66B | 360.35M | -149.57M | -81.27M | -2.69 |
| ABT | 117.70 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 392.23 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.61 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.92 | 112.92B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.98 | 40.88B | 6.60B | 4.16B | 490.10M | 2.34 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Oppenheimer Asset Management Inc. Sells 3,974 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Here's Why You Should Retain Glaukos (GKOS) Stock for Now - MSN
Glaukos Revolutionizes Glaucoma Treatment with iDose TR Approval - TipRanks
Brown Capital Management LLC's Strategic Reduction in Glaukos Co - GuruFocus.com
(GKOS) Long Term Investment Analysis - Stock Traders Daily
Glaukos Co. (NYSE:GKOS) Shares Bought by WCM Investment Management LLC - MarketBeat
Principal Financial Group Inc. Sells 9,441 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Lisanti Capital Growth LLC Sells 20,320 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates - MSN
Glaukos Announces Participation in Upcoming Investor Conferences - BioSpace
William Blair Comments on Glaukos' Q4 Earnings (NYSE:GKOS) - MarketBeat
Glaukos to Present at 5 Major Healthcare Investor Conferences in Q4 2024 | GKOS Stock News - StockTitan
Glaukos Corporation (NYSE:GKOS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Glaukos stock soars to all-time high of $139.53 amid robust growth - Investing.com
Glaukos Corporation (NYSE:GKOS) Q3 2024 Earnings Call Transcript - MSN
Glaukos price target raised to $145 from $135 at Wells Fargo - Yahoo Finance
Glaukos Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Glaukos price target raised to $140 from $139 at BTIG - TipRanks
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market | Futu - WICZ
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - MSN
Glaukos (NYSE:GKOS) Shares Gap DownHere's What Happened - MarketBeat
Glaukos (NYSE:GKOS) Releases Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Earnings call: Glaukos reports strong Q3 growth, raises 2024 guidance - Investing.com
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
JPMorgan Chase & Co. Issues Positive Forecast for Glaukos (NYSE:GKOS) Stock Price - MarketBeat
Piper Sandler reaffirms stock target on Glaukos post-Q3 beat - Investing.com
BTIG reiterates Buy on Glaukos stock as strong iDose sales support growth outlook - Investing.com
Glaukos Co. (NYSE:GKOS) Receives $130.45 Average PT from Analysts - MarketBeat
Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sal - GuruFocus.com
Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sales and Raised Guidance Amid ... - Yahoo Finance
Glaukos Reports Net Sales Increase of 24 Percent in Third Quarter 2024 Behind Strong Glaucoma Sales - Vision Monday
Glaukos reports Q3 adjusted EPS (28c), consensus (48c) - TipRanks
Glaukos Corp. Reports Record Third-Quarter Sales Growth - TipRanks
Glaukos Announces Third Quarter 2024 Financial Results - BioSpace
Glaukos Corp earnings beat by $0.20, revenue topped estimates - Investing.com
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Glaukos: Q3 Earnings Snapshot - San Francisco Chronicle
Glaukos Corp (GKOS) Q3 2024 Earnings: EPS of ($0.39) Beats Estimates, Revenue Surges to $96.7 Million - GuruFocus.com
Glaukos Reports Record Sales Despite Net Loss - TipRanks
Q3 2024 Glaukos Corp Earnings Call Transcript - GuruFocus.com
Glaukos Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Glaukos Co. (NYSE:GKOS) Shares Sold by New York State Common Retirement Fund - MarketBeat
Glaukos president sells $316,156 in stock By Investing.com - Investing.com Australia
Glaukos Co. (NYSE:GKOS) COO Sells $316,156.75 in Stock - MarketBeat
Glaukos president sells $316,156 in stock - Investing.com India
Earnings To Watch: Glaukos Corp (GKOS) Reports Q3 2024 Result - GuruFocus.com
Possible Bearish Signals With Glaukos Insiders Disposing Stock - Simply Wall St
Creative Planning Purchases 4,937 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):